Denali Therapeutics Inc. DNLI Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s additional paid-in capital?
- Denali Therapeutics Inc. (DNLI) reported additional paid-in capital of $3.1B in Q1 2026.
- How has Denali Therapeutics Inc.'s additional paid-in capital changed year-over-year?
- Denali Therapeutics Inc.'s additional paid-in capital increased by 11.3% year-over-year, from $2.79B to $3.1B.
- What is the long-term trend for Denali Therapeutics Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s additional paid-in capital has grown at a 15.3% compound annual growth rate (CAGR), from $1.5B to $3.06B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.